Jin Medical International (ZJYL) Current Deferred Revenue (2022 - 2025)

Jin Medical International (ZJYL) has reported Current Deferred Revenue for 4 consecutive years, with $495357.0 the latest figure, recorded in Q3 2025.

• Quarterly Current Deferred Revenue fell 26.22% year-over-year to $495357.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $495357.0 (down 26.22% YoY) and the FY2025 annual result came in at $495357.0, down 26.22% from the prior year.
• Current Deferred Revenue improved to $495357.0 in Q3 2025 per ZJYL's latest filing, from $346410.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for ZJYL reached as high as $830305.0 in Q3 2022 and fell as low as $346410.0 in Q1 2025.
• A 4-year average of $594531.3 and a median of $561146.0 in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue declined 2.52% — and 2025, when it slumped 36.67%.
• Year by year, Current Deferred Revenue stood at $830305.0 in 2022, then dropped by 14.48% to $710099.0 in 2023, then retreated by 5.45% to $671414.0 in 2024, then declined by 26.22% to $495357.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $495357.0, $346410.0, and $671414.0 for Q3 2025, Q1 2025, and Q3 2024 respectively.